Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SpePharm Holding
Amsterdam, Netherlandsspepharm.com ↗
- Ownership
- Private
- Employees
- ~1250
- Development stage
- Other
01
Overview
SpePharm Holding commercialized a portfolio of specialty hospital medicines (Savene, MuGard, Xerotin, PROther, Dantrium brands) in critical care and oncology supportive settings, later acquired by Norgine through a joint venture (SpePharm AG) for pan-European marketing.
- Therapeutic areas
- GastroenterologyNeurologyOtherDermatologyOncology
- Modalities
- Small moleculeDeviceProtein
- Industry
- Biotech
02
Partnerships
NorgineSignet Healthcare PartnersTVM Capital Life ScienceSanders Morris Harris Private EquityIndevus PharmaceuticalsBioAlliance Pharma
Beyond the preview
Go deeper on SpePharm Holding.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpePharm Holding.